US20030220551A1 - Device for assessing perfusion failure in a patient by measurement of blood flow - Google Patents

Device for assessing perfusion failure in a patient by measurement of blood flow Download PDF

Info

Publication number
US20030220551A1
US20030220551A1 US10/357,996 US35799603A US2003220551A1 US 20030220551 A1 US20030220551 A1 US 20030220551A1 US 35799603 A US35799603 A US 35799603A US 2003220551 A1 US2003220551 A1 US 2003220551A1
Authority
US
United States
Prior art keywords
device
patient
mucosal surface
sensor
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/357,996
Inventor
Victor Kimball
Max Weil
Wanchun Tang
Jose Bisera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weil Institute of Critical Care Medicine
Optical Sensors Inc
Original Assignee
Optical Sensors Inc
Institute of Critical Care Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/498,932 priority Critical patent/US5579763A/en
Priority to US71020896A priority
Priority to US93959197A priority
Priority to US09/099,293 priority patent/US6055447A/en
Priority to US09/160,224 priority patent/US6216024B1/en
Priority to US09/285,409 priority patent/US6258046B1/en
Priority to US09/866,042 priority patent/US20010025151A1/en
Priority to US10/357,996 priority patent/US20030220551A1/en
Application filed by Optical Sensors Inc, Institute of Critical Care Medicine filed Critical Optical Sensors Inc
Assigned to OPTICAL SENSORS INCORPORATED reassignment OPTICAL SENSORS INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIMBALL, VICTOR E.
Assigned to INSTITUTE OF CRITICAL CARE MEDICINE reassignment INSTITUTE OF CRITICAL CARE MEDICINE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BISERA, JOSE, TANG, WANCHUN, WEIL, MAX HARRY
Priority claimed from US10/668,750 external-priority patent/US20040127800A1/en
Publication of US20030220551A1 publication Critical patent/US20030220551A1/en
Assigned to Weil Institute of Critical Care Medicine reassignment Weil Institute of Critical Care Medicine CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: INSTITUTE OF CRITICAL CARE MEDICINE
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14542Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/0059Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0084Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026Measuring blood flow
    • A61B5/0261Measuring blood flow using optical means, e.g. infra-red light
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14539Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1468Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
    • A61B5/1473Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/41Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/412Detecting or monitoring sepsis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/42Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813Specially adapted to be attached to a specific body part
    • A61B5/6814Head
    • A61B5/682Mouth, e.g., oral cavity; tongue; Lips; Teeth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/06Measuring blood flow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/12Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/0059Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission

Abstract

A device is provided for assessing impairment of blood circulation in a patient, such as that in perfusion failure, by measurement of blood flow adjacent a mucosal surface accessible by a mouth or nose and connecting with the gastrointestinal tract or upper respiratory/digestive tract of a patient. The device includes a blood-flow sensor adapted to be positioned adjacent a mucosal surface with a patient's body and measuring blood flow in adjacent tissue and a PCO2 sensor adapted to be positioned adjacent the mucosal surface and measuring PCO2. In addition a pH sensor may be used in combination with the blood flow determination. The invention affords rapid measurement and detection of perfusion failure.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation-in-part of U.S. Ser. No. 09/866,042, filed May 24, 2001, which is a continuation of U.S. Ser. No. 09/285,409, filed Apr. 2, 1999, issued on Jul. 10, 2001 as U.S. Pat. No. 6,258,046, which is a continuation-in-part of U.S. Ser. No. 09/160,224, filed Sep. 24, 1998, issued on Apr. 10, 2001 as U.S. Pat. No. 6,216,024, which is a continuation-in-part of U.S. Ser. No. 09/099,293, filed Jun. 18, 1998, issued Apr. 25, 2000 as U.S. Pat. No. 6,055,447, which is a continuation-in-part of U.S. Ser. No. 08/939,591, filed Sep. 29, 1997, abandoned, which is a continuation-in-part of U.S. Ser. No. 08/710,208, filed Sep. 13, 1996, abandoned, which is a continuation-in-part of U.S. Ser. No. 08/498,932, filed Jul. 6, 1995, which issued Dec. 3, 1996 as U.S. Pat. No. 5,579,763.[0001]
  • TECHNICAL FIELD
  • The present invention relates generally to methods and devices for assessing perfusion failure in a patient. More particularly, the invention relates to assessment of perfusion failure in a patient by measuring blood flow in a mucosal tissue in the body of a patient. [0002]
  • BACKGROUND OF THE INVENTION
  • Very low blood flow, or low “systemic perfusion,” is typically due to low aortic pressure and can be caused by a number of factors, including hemorrhage, sepsis and cardiac arrest. The body responds to such stress by reducing blood flow to the gastrointestinal tract to spare blood for other, more critical organs. Thus, when there is a reduced flow of blood from the heart, the body directs a higher portion of blood to critical organs, such as the brain, which will not survive long without a continuous supply of blood, while restricting the flow to less critical organs, whose survival is not as threatened by a temporary large reduction in blood flow. For example, blood flow to the splanchnic vasculature which supplies the stomach and intestines, and also the esophagus and oral/nasal cavity, is drastically reduced when there is a reduced blood flow from the heart. For this reason, decreased blood flow to the splanchnic blood vessels is thus an indication of perfusion failure in a patient. Physicians commonly take advantage of this phenomenon by taking CO[0003] 2 and pH measurements in the stomach and intestine to assess perfusion failure.
  • Assessment of CO[0004] 2 concentration in the less critical organs, i.e., those organs to which blood flow is reduced during perfusion failure, has been useful in perfusion assessment. Carbon dioxide production, which is associated with metabolism, continues in tissues even during conditions of low blood flow. The concentration of CO2 builds-up in tissues experiencing low blood flow because CO2 is not rapidly carried away. This CO2 build-up (an increase in partial pressure of CO2 (PCO2)) in the less critical organs in turn results in a decrease in pH in nearby tissue. Therefore, perfusion failure is commonly assessed by measuring pH or PCO2 at these sites, especially in the stomach and intestines. For examples of catheters used to assess pH or PCO2 in the stomach or intestines, see, e.g., U.S. Pat. Nos. 3,905,889; 4,016,863; 4,632,119; 4,643,192; 4,981,470; 5,105,812; 5,117,827; 5,174,290; 5,341,803; 5,411,022; 5,423,320; 5,456,251; and 5,788,631.
  • The inventors have found that increases in PCO[0005] 2 may be measured throughout the body, including in accessible organs and tissues fed by splanchnic vessels, and used to assess perfusion failure. For example, the inventors have found that a useful measurement of perfusion failure can be obtained by measuring CO2 in the upper respiratory/digestive tract. In U.S. Pat. No. 5,579,763, a method is described that can be used to accurately assess perfusion failure by measuring PCO2 in the patient's esophagus, rather than in the less accessible stomach and/or intestine as previously practiced in the art. Tests showed that measurements of PCO2 in the esophagus are closely correlated with aortic pressure, and, furthermore, that measurements made in the esophagus are even more closely correlated to aortic pressure than measurements of CO2 in the stomach. More recently, in co-pending, commonly assigned U.S. Ser. No. 09/160,224, the inventors further showed that PCO2 measurements in a patient's mucosal tissues (e.g., mouth, nasal mucosa, and throat) are also closely correlated to aortic pressure. As disclosed in U.S. Ser. No. 09/160,224, the CO2 sensor may be placed at a site within the oral-nasal cavity (e.g., under the tongue at a site in contact with the tongue or the floor of the mouth) where it effectively measures CO2 in the tissue. Since carbon dioxide can readily pass through mucosal surfaces, CO2 generated by metabolic activity occurring in tissue below the mucosal surface that is not carried away by blood flow readily migrates through the mucosal surface, where its build-up provides a good measure of perfusion failure. Placement of a CO2 sensor adjacent a mucosal surface of the upper respiratory/digestive tract thus provides a very good quantification of perfusion failure at all times, including the most critical minutes after the onset of perfusion failure when treatment is likely to be most effective. Thus, mucosal measurements of tissue perfusion can be used to assess perfusion failure in patients.
  • However, PCO[0006] 2 and pH are indirect measures of blood flow in tissue, being based upon the build-up of metabolites that result from poor perfusion. In addition, measurements of pH may be complicated by the presence of saliva, food, or stomach acids. CO2 measurements may be affected by ambient CO2 , and, since they depend on equilibration with tissue CO2 levels, are slow. Thus, there is a need for a more direct method for measuring blood flow in a tissue, to more accurately assess perfusion failure and to monitor the effectiveness of methods taken to increase perfusion, e.g., blood infusion or the like.
  • BRIEF SUMMARY OF THE INVENTION
  • Methods and devices are provided for assessing impairment of circulatory function in a patient, such as that in perfusion failure, by measurement of blood flow adjacent a mucosal surface accessible via the mouth or nose that connects with the GI tract and/or upper respiratory/digestive tract of a patient. The perfusion of a tissue is a function of both the velocity of blood cells flowing through tissue, and of the number of blood cells, so that the blood flow through tissue is a more direct measurement of tissue perfusion than pH or CO[0007] 2 measurements. Previously, the belief in the art was that decreased blood flow was a localized phenomenon during perfusion failure. It has now been discovered that decreased blood flow, decreased pH and increases in tissue CO2 occur throughout the body during perfusion failure, and in particular occur not only in the stomach, jejunum, colon and rectum, but also in the esophagus, throat, mouth, nose and associated areas. Thus, new and useful methods and devices are now provided, for assessing perfusion failure and perfusion levels in a patient by measuring blood flow in tissues of the GI tract and/or of the upper respiratory/digestive tract of a patient.
  • In one embodiment, then, a method is provided for assessing impairment of circulatory function, such as that in perfusion failure in a patient. The method comprises introducing a blood-flow sensor adjacent a mucosal surface that is accessible via the mouth or nose and connects with the GI tract or the upper respiratory/digestive tract of a patient, measuring blood flow in the tissue adjacent the sensor, and providing that measurement for assessment of perfusion failure. Specifically, a blood-flow sensor is placed adjacent a mucosal surface within a patient's body, preferably without passing the sensor down through or beyond the patient's epiglottis, most preferably within the oral or a nasal cavity of the patient. The blood-flow sensor may be introduced sublingually to one side of the frenulum. The invasiveness of such a technique is minimal, being substantially no more than in the use of an oral thermometer. Alternatively, the blood flow sensor may be introduced and placed adjacent any mucosal surface accessible via the mouth or nose including connections to the upper respiratory/digestive tract or the gastrointestinal tract. Preferably, the sensor is a laser-Doppler sensor. The output of the sensor can be detected by a device which electronically converts the sensor output to provide the blood flow in a form that is easily understood by persons viewing the display. The device can optionally further sense the rate of change of blood flow with time to indicate the patient's condition. [0008]
  • Accordingly, in another embodiment the invention features a device for assessing perfusion failure in a patient, where the device is composed of a laser-Doppler blood-flow sensor means for measuring blood flow in a tissue, the sensor means being adapted for lying adjacent a mucosal surface in a patient's body, e.g. in the upper respiratory/digestive tract of a patient, and measuring blood flow in vessels in the mucosal tissue; and an indicating means connected to the sensor means, wherein the indicating means indicates a degree of perfusion failure of the patient associated with the detected blood flow. The device may also include a positioning means for positioning the sensor means adjacent the mucosal surface. In one embodiment, the “positioning means” is a holder designed to fit within the mouth of the patient and hold the sensor in place adjacent the mucosal surface. For example, the holder may be designed to position the sensor adjacent the tongue of a patient, or to position the sensor between the inside of a lip and gum of the patient. Alternatively, the positioning means may be a holder designed to fit within a nares of the patient and hold the sensor in place adjacent the mucosal surface. Alternatively, the positioning means may be adapted to position the sensor adjacent any mucosal surface that connects to the upper respiratory/digestive tract or the gastrointestinal tract, which is accessible via the mouth or nose. [0009]
  • In a further embodiment the invention features a device for use with a blood-flow sensor assembly for assessing perfusion failure of a patient. The device is composed of a sensor holder with a sublingual holder inner portion shaped to fit in the mouth of a patient under the patient's tongue, said holder forming at least one holder passage optionally extending from said holder outer portion to said sublingual holder portion. [0010]
  • In a further embodiment the invention comprises measuring blood flow with a blood-flow sensor and additionally making an indirect measurement of blood flow by making, e.g., a CO[0011] 2 measurement or a pH measurement, or by making all three such kinds of measurements.
  • One advantage of the invention is that perfusion can be rapidly assessed in a patient, with measurements being made in just a few seconds. [0012]
  • Another advantage of the invention is that perfusion can be assessed in a patient in a minimally invasive manner, and with minimal discomfort or risk of harm to the patient. [0013]
  • Another advantage of the invention is that perfusion can be assessed in a patient without interference in the measurement by ambient levels of CO[0014] 2 and without substantial drift of the measurement when used in a continuous monitoring application.
  • Another advantage of the invention is that perfusion can be assessed in a patient without interference with the measurement by the pH of fluids or food near the sensor. [0015]
  • Another advantage of the invention is that perfusion can be readily assessed in a patient suffering from perfusion failure associated with any of a variety of causes, including, but not limited to physical trauma, infection, hypothermia, cardiogenic shock (e.g., acute myocardial infarction, aneurysm, or arrhythmia), obstructive shock (e.g., pulmonary embolism), hypovolemic shock (e.g., due to hemorrhage or fluid depletion), and distributive shock (e.g., due to sepsis, exposure to toxins, or anaphylaxis). The sensitivity of the methods and devices of the invention further allow for assessment of perfusion across a wide range of perfusion failure severity, thereby providing a means to accurately monitor the patient's condition. [0016]
  • Still another advantage of the invention is that the devices and methods can be readily adapted for use in alert, semi-conscious, or unconscious patients, and can be further adapted for accurate assessment of perfusion in a patient for a period lasting for only seconds to minutes to hours or days. [0017]
  • The novel features of the invention are set forth with particularity in the appended claims. The invention will be best understood from the following description when read in conjunction with the accompanying drawings. [0018]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph showing variation in blood flow in various tissues with time, during an experiment on rats where blood was withdrawn to simulate hemorrhage and so induce perfusion failure, and during reinfusion of blood to allow recovery. [0019]
  • FIG. 2 is a partial sectional view showing a sensor of the present invention in place in one of many acceptable positions within the GI tract of a patient. [0020]
  • FIG. 3 is an isometric view showing a sensor of the present invention as it is introduced into the mouth of a patient, for sublingual placement. [0021]
  • FIG. 4 is a sectional view of a sensor assembly and holder constructed in accordance with an embodiment of the invention, shown lying in a patient's mouth. [0022]
  • FIG. 5 is an isometric view of the holder of FIG. 4. [0023]
  • FIG. 6 is a sectional view of a sensor assembly and holder of another embodiment of the invention, shown holding a sensor between a lip and teeth of a patient. [0024]
  • FIG. 7 is a front isometric view of the holder of FIG. 6. [0025]
  • FIG. 8 is a sectional view of a sensor assembly and holder of another embodiment of the invention, shown holding a sensor in the nose of a patient.[0026]
  • DETAILED DESCRIPTION OF THE INVENTION
  • Definitions and Nomenclature: [0027]
  • Before the present devices, apparatus and methods are disclosed and described, it is to be understood that this invention is not limited to sensor designs, measurement techniques, or the like, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. [0028]
  • It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. [0029]
  • We define the term “perfusion failure” as used herein to mean a reduction in blood flow associated with maldistribution of blood through the circulatory system and a reduction in blood flow to a less critical tissue(s) and/or organ(s) relative to blood flow in vital (critical) tissues and organs (e.g., the brain and heart). In general, “perfusion failure” is meant to encompass reduction in blood flow associated with a decrease in blood flow significantly or substantially below that associated with normal perfusion. [0030]
  • We define the term “measurement” as used herein to refer to a single measurement or a series of measurements made over time, and which may be taken continuously or intermittently (e.g., at selected time intervals). [0031]
  • We define the term “mucosal surface” as used herein to refer to a surface of a mucous membrane containing or associated with mucus secreting glands, and which lines body passages, tubular structures, and organs, consisting of epithelium, lamina, propria, and, in the digestive tract, a layer of smooth muscle and encompasses, for example, the nasal passages (including the nasal cavity, the middle nasal conchae, the inferior nasal conchae, the choana, the naso-pharyngeal opening of the auditory tube and the auditory tube), the oral cavity (including the mouth and spaces within the mouth such as the sublingual area, the hard palate, the soft palate, and the gingival surfaces), the pharynx, the oropharyngeal passage, the esophagus, the stomach, the jejunum, the colon, and the rectum. [0032]
  • We define the terms “gastrointestinal tract” and “GI tract” as used herein to encompass the entire tract from esophagus to rectum, including, e.g., the esophagus, the stomach, the jejunum, the colon, and the rectum. [0033]
  • We define the term “upper respiratory/digestive tract” as used herein to mean the region of the upper respiratory tract and digestive tract above the stomach. We define the “upper respiratory/digestive tract” to encompass the nasal passages (including the nares (or vestibule of the nasal cavity), the nasal cavity, middle nasal conchae, inferior nasal conchae, choana, the naso-pharyngeal opening of the auditory tube, and the auditory tube), the oral cavity (commonly called the mouth and including the spaces within the mouth such as the floor (e.g., sublingual area) and roof of the mouth (e.g., hard palate), the soft palate, the regions between the lips and gums, and the cheeks and gums), the pharynx (including the nasopharynx, oropharynx and laryngopharynx) and oropharyngeal passage (collectively, commonly called the throat) and the esophagus. [0034]
  • We define the term “auditory tube” (Eustachian tube) as used herein to mean the channel through which the tympanic cavity (middle ear) communicates with the nasopharynx. [0035]
  • We define the term “nasopharynx” as used herein to mean the part of the pharynx that lies above the soft palate; anteriorly it opens into the nasal cavity; inferiorly, it communicates with the oropharynx via the pharyngeal isthmus; laterally it communicates with tympanic cavities via auditory tubes. [0036]
  • We define the term “oral-nasal cavity” as used herein to mean the region of the upper respiratory/digestive tract encompassing the nasal passages (including the nares (or vestibule of the nasal cavity), the nasal cavity, the middle nasal conchae, the inferior nasal conchae, the choana and the pharyngeal opening of the auditory tube), the oral cavity (including the mouth and spaces within the mouth such as the floor (e.g., sublingual area) and roof of the mouth (e.g., hard palate), the soft palate, the regions between the lips and gums, and the inner cheeks and gums), and the pharynx (including the nasopharynx, oropharynx and laryngopharynx) and oropharyngeal passage (collectively, commonly called the throat) extending to the top surface of and in the region of the epiglottis. [0037]
  • We define the term “sublingual” as used herein to refer to a region below or beneath the tongue. [0038]
  • We define the term “adjacent” as used herein (e.g., “adjacent the mucosal surface”) to mean near or against, e.g., at a distance from the mucosal surface that allows acceptably accurate measurement of blood flow by blood-flow sensor. [0039]
  • We define the term “patient” as used herein to mean a mammalian subject, preferably a human subject, that has, is suspected of having, or is or may be susceptible to a condition associated with low blood flow, and thus perfusion failure. [0040]
  • The present invention is based on the inventors' discovery that blood flow decreases throughout the body during perfusion failure, rather than as only a localized phenomenon as previously believed in the art. Evidence for this is seen, e.g., in that tissue CO[0041] 2 increases in esophagus and sublingual tissue during perfusion failure, as disclosed by the inventors in U.S. Ser. No. 09/160,224. Further evidence of this is shown in FIG. 1 where blood flow in various tissues of experimental animals was measured by the deposition of small beads measured at autopsy. The methods and devices of the invention measure blood flow in tissue at a convenient site within the GI tract or within the upper respiratory/digestive tract, and are thus performed in a minimally invasive manner. In general, these measurements are made by placing a blood-flow sensor such as a laser-Doppler sensor or an ultrasound Doppler adjacent a mucosal surface at a selected site within the upper respiratory/digestive tract and using the sensor to measure blood flow at the selected site. Such measurements may also be made using imaging techniques such as MRI, optical imaging, angiography techniques and other methods as would be known to those skilled in the art.
  • As blood flows through tissue, the blood cells and the fluid blood plasma move at similar rates. Light, as may be provided by a laser-Doppler blood-flow device, and ultrasound, as may be provided by an ultrasound-Doppler blood-flow device, can pass through tissue to illuminate or impinge upon blood cells moving through tissue of interest. When light or ultrasound reflects off moving blood cells its frequency is shifted in a velocity-dependent manner, a phenomenon known as the “Doppler shift.” This phenomenon can be used to measure the velocity of blood cells flowing through the tissue so illuminated or so subject to ultrasound. In addition, a laser-Doppler device or ultrasound-Doppler device may be used to measure the ratio of moving blood cells to the non-moving cells located in the measurement volume of the sensor. The measurement volume of tissue in which this measurement is made may be calculated using scattering theory and the geometry of the illuminating and collecting sites, or may be measured using standard calibration techniques; either of which is routinely done with laser-Doppler devices. The total blood flow may be calculated from these three parameters: 1) the number of cells within the measurement volume, 2) the velocity of the moving cells, and 3) the measurement volume. [0042]
  • Methods and techniques for using laser-Doppler techniques and devices to measure blood flow are known in the art, and may be found in such references as, e.g., U.S. Pat. No. 3,511,227 to Johnson, U.S. Pat. No. 4,596,254 to Adrian et al., and U.S. Pat. No. 4,590,948 to Nilsson. [0043]
  • Methods and techniques for using ultrasound-Doppler techniques and devices to measure blood flow are known in the art, and may be found in such references as U.S. Pat. No. 4,324,258 to Huebscher et al. and U.S. Pat. No. 4,759,374 to Kierney et al. [0044]
  • Thus, laser-Doppler, ultrasound-Doppler, and other blood-flow measurement devices can be used to provide direct measures of blood flow in tissues. The present invention provides novel methods using such measurements to detect and quantify blood flow in tissues susceptible to low blood flow effective to detect perfusion failure in a patient. [0045]
  • In order to assess perfusion failure in a patient, one first determines the expected range of blood-flow measurements for subjects of similar age and health status as the patient. Normal levels of blood flow may vary with the age of the subject. Health status may also be an important variable, since, for example, blood flow in a diabetic subject may differ from that of a subject not suffering from diabetes. Next, the blood flow in a mucosal tissue of the patient is determined. The blood-flow value is compared with the expected value for a normal subject determined in the first step; patient blood-flow values that are significantly lower than the normal values indicate perfusion failure. In addition, the rate-of-change of the patient's blood flow is measured over time with the blood-flow sensor. Rising values of blood flow indicate recovery, while declining values of blood flow indicate a worsening of the patient's condition. [0046]
  • The correlation of perfusion failure with decreased blood flow in several bodily tissues, including sublingual blood flow in particular, as well as the correlation of perfusion recovery and a corresponding increase in sublingual blood flow as blood volume recovers, was tested in an animal model that simulates a sudden loss or shedding of blood, such as might be caused by a gunshot wound or other severe wound. Perfusion recovery was simulated by subsequently reperfusing the animals with a blood infusion. Blood flow in the several tissues was assessed by counting (at autopsy) the numbers of colored microspheres deposited in various tissues under the indicated conditions, as described in Hale et al. ([0047] Circulation 78:428-434, 1988). The results are shown in FIG. 1. Blood flow in a tissue as a percentage of baseline (control) blood flow is plotted as a function of time during hemorrhage (induced blood-loss) and reinfusion of blood in an experimental animal. At the beginning of the test (BL), just prior to the time-point labeled “0,” considerable blood was drawn from an animal that was previously in good health, the blood being drawn within a period of a few minutes. Aortic pressure drops rapidly during the first few minutes of such a test. In a subsequent period of about two hours, the aortic pressure remained about 40-50% below normal. The graph shows that tongue and sublingual blood flow decreased to about 35% during the first hour, showing a more dramatic response than other tissues. These data show that an decrease in sublingual blood flow is directly correlated with the effects of blood loss, i.e. perfusion failure.
  • The relationship of sublingual blood flow and recovery of blood volume (i.e., during perfusion recovery) was tested by infusing the animal with a blood infusion at 120 minutes. Aortic pressure rapidly increases during this period; similarly, sublingual blood flow rapidly recovered. [0048]
  • In addition to blood flow, as described above, PCO[0049] 2 or pH may also be measured in the animal or patient, at the same time or shortly before or shortly after such blood-flow measurements are made, to provide further information useful for assessing perfusion failure in an animal or a patient. PCO2 and pH may be measured using any suitable technique, as will be appreciated by those skilled in the art.
  • For example, PCO[0050] 2 may be measured using a CO2 sensor such as a pH-sensing PCO2 sensor. Such PCO2 sensors may have, for example, a membrane that is permeable to CO2, and that separates a sodium bicarbonate or carbonic acid (HCO3) solution from the environment. A pH sensor in the device measures the pH of the sodium bicarbonate solution. Two exemplary CO2 sensors of this type are manufactured by Microelectrode, Inc. and Nihon Kohden (ISFET PCO2 sensor).
  • Alternatively, the CO[0051] 2 sensor is an optical PCO2 sensor. Structures, properties, functions, and operational details of fiber optic chemical sensors can be found in U.S. Pat. Nos. 4,577,109; 4,785,814; and 4,842,783, as well as in Seitz, “Chemical Sensors Based on Fiber Optics,” Anal. Chem. 56(1):16A-34A (1984). Fiber optic sensors for monitoring CO2 that may be suitable for use in the present invention include, but are not limited to, those described in U.S. Pat. Nos. 4,800,886; 4,892,383; 4,919,891, 5,006,314; 5,098,659; 5,280,548; and 5,330,718. Other exemplary fiber optic CO2 sensors are described in Peterson et al. “Fiber Optic Sensors for Biomedical Applications,” Science 224(4645):123-127 (1984) and Vurek et al. “A Fiber Optic PCO2 Sensor,” Annals Biomed. Engineer. 11:499-510 (1983).
  • A suitable optical CO[0052] 2 sensor is described in U.S. Pat. No. 5,714,121 ('121) to Alderete et al., which pertains to an optical CO2 sensor and method of manufacture thereof; a preferred sensor system and method of using the aforementioned optical CO2 sensor is described in U.S. Pat. No. 5,672,515 ('515) to Furlong. In general, the sensor of the '121 patent is composed of a single optical fiber having a distal tip and a proximal region for communication with a means for receiving a signal from the distal tip. Light of a predetermined wavelength is directed through the optical fiber towards the distal tip, and emitted fluorescent light returns along the fiber to be detected and converted to a CO2 concentration value. A capsule, composed of a CO2-permeable silicone material, is arranged over the distal tip at a predetermined position. The capsule contains an indicator solution having a suitable pH-sensitive indicator component, generally a fluorescent dye, and substantially no air. Examples of fluorescent dyes include without limitation fluorescein, carboxyfluorescein, seminaphthorhodafluor, seminaphthofluorescein, naphthofluorescein, 8-hydroxypyrene 1,3,6-trisulfonic acid, trisodium salt (“HPTS”) and dichlorofluorescein, with HPTS particularly preferred. A sealing means provides a liquid-tight seal and affixes the capsule onto the distal tip.
  • Optical CO[0053] 2 sensors are generally used by contacting the distal end of the sensor with a mucosal surface as described herein. Light of a predetermined wavelength is directed from an external source, through the optical fiber, impinging distally on the encapsulated indicator composition. The intensity of the emitted fluorescent light returning along the fiber is directly related to the concentration of CO2 in the sample, as a result of the pH-sensitive indicator material present at the fiber tip (i.e., the pH of the indicator solution is directly related to CO2 concentration, as a result of carbonic acid formation). The emitted light is carried by the optical fiber to a device where it is detected and converted electronically to a CO2 concentration value. The sensor may additionally have a reference dye present in the indicator composition. The intensity of the light emitted from the reference dye may be used to compensate, via ratioing, the signal obtained from the indicator. A more preferred system for determining PCO2 is described in the '515 patent, directed to a simultaneous dual excitation/single emission fluorescent sensing method, wherein light of two different wavelengths is used to excite a single fluorescent indicator species, with one of the two wavelengths at the isosbestic point. The two fluorescence emission signals that result are ratioed to provide the desired measurement.
  • Suitable pH sensors include optical pH sensors as described in U.S. Pat. Nos. 5,536,783 and 5,607,644 to Olstein et al. Such optical sensors include a chemical pH sensor means, capable of responding to changes in pH in nearby tissues and fluids, that is incorporated into a fiber optic waveguide assembly so as to interact with the environment into which the pH sensor means is placed. The sensor may be placed in a patient's body, and more particularly, may be placed adjacent a mucosal surface in a patient's body. Typically, the responses of the chemical sensor cause changes in the optical properties of the chemical sensor/optical waveguide assembly, so that pH changes near the tip of the assembly may be monitored and assessed by the user at another portion of the apparatus, e.g., at a portion of the apparatus remaining external to the patient's body. For example, as described in the aforementioned U.S. patents, the pH sensor means may comprise a fluorescent poly(urethrane) copolymer that fluoresces in response to irradiation, wherein the fluorescence is dependent on the pH of the environment being monitored. [0054]
  • The results of experiments in the animal model, as shown in FIG. 1, can be extrapolated to represent a human subject suffering perfusion failure, such as that associated with a gunshot wound or a severe cut from machinery or a knife. Thus, a patient will suffer a rapid decrease in aortic pressure during blood loss, until the outflow of blood is stopped by application of pressure or other means to stop bleeding. The present invention takes advantage of the relationship between blood flow (in the GI tract or the upper respiratory/digestive tract, including in such tissues as sublingual, tongue, stomach and so forth) and perfusion failure or perfusion level, to provide methods and devices to assist a physician or other health care provider in the diagnosis and treatment of a patient having or susceptible to a condition associated with perfusion failure. [0055]
  • For example, although assistance from a paramedic or other person may be available shortly after the initial primary insult, it may take thirty minutes or more for the patient to reach a hospital. This lapse in time may make it difficult to accurately assess the condition of the patient and the presence and/or severity of perfusion failure. Measuring and/or monitoring sublingual blood flow according to the present invention allows the physician or other healthcare provider to readily detect the level of blood flow relative to normal, as well as the rate of change of blood flow. A rapid decrease in blood flow suggests that the patient has suffered a loss of blood within the last hour or so, while low blood flow indicates the patient presently suffers from a low level of aortic pressure and perfusion failure. In this manner the invention can be used to assess the patient's condition, allowing for appropriate and rapid selection of an appropriate therapy. [0056]
  • The present invention can also be used to monitor the efficacy of reperfusion or other therapeutic regimen to treat perfusion failure in the patient. For example, if the physician, paramedic, or other emergency provider determines that a transfusion of blood or blood components is indicated, and the transfusion is successful in rapidly increasing aortic pressure (such as that illustrated in FIG. 1 from 120 minutes onward), then this success will be reflected by a rapid recovery in blood flow (as illustrated in FIG. 1 from 120 minutes onward). FIG. 1 shows that sublingual blood flow measurements provide a good indication of the level of perfusion failure. [0057]
  • In the present invention, the inventors disclose that a useful measurement of perfusion failure can be obtained by measuring blood flow anywhere in the GI tract or the upper respiratory/digestive tract. Although FIG. 2 illustrates the upper portion of the GI tract, it is to be understood that the invention may be practiced by placement of a blood-flow sensor adjacent any mucosal surface accessible by the outh or nose and connecting with the GI tract or upper respiratory/digestive tract. Accordingly, by way of illustration, FIG. 2 shows the upper respiratory/digestive system or tract A of a person, and particularly including the nasal passage B, the oral cavity C, and the upper portion D of the throat that extends to the top of the epiglottis E. The upper respiratory/digestive tract includes, without limitation, the esophagus F, and the gastrointestinal tract includes, without limitation, the esophagus F, the esophageal sphincter G, the stomach H, and the intestines J. Insertion of a catheter [0058] 10 with a blood-flow sensor 12, through the nose or mouth B, C, past the epiglottis E, and into the esophagus F so that the end 14 of the catheter with the sensor 12 thereat lies adjacent a mucosal surface within the esophagus.
  • Preferably, the sensor may be positioned in the upper respiratory/digestive tract A, preferably with the sensor lying above, at the surface of, or at the epiglottis E so it does not have to pass by it. More preferably, the sensor is placed at a site within the oral-nasal cavity, e.g., within the nasal cavity, the mouth (e.g., under the tongue at a site in contact with the tongue or the floor of the mouth, between a region of the lip and gum or the cheek and gum, the roof of the mouth, or the soft palate), or at a site within the pharynx. Most preferably, the sensor is placed adjacent a mucosal surface at a site that will avoid the patient's gag reflex or otherwise minimize discomfort. [0059]
  • The blood-flow sensor lies adjacent a mucosal surface in the upper respiratory/digestive tract A, in order that it effectively measures blood flow in the tissue. Placement of a blood-flow sensor adjacent a mucosal surface of the upper respiratory/digestive tract A according to the present invention provides a very good quantification of perfusion failure at all times, including the most critical minutes after the onset of perfusion failure when treatment is likely to be most effective. [0060]
  • FIG. 3 shows one embodiment of a device or apparatus of the present invention, wherein a tube [0061] 20 containing a blood-flow sensor 22 at its front end, is inserted into the oral cavity and placed under the tongue T of the patient, preferably to one side of the frenulum V. After insertion, it might be desirable if the mouth M of the patient is kept closed around the tube. However, as with other instruments commonly inserted through the mouth, and as with a patient in a critical condition, the patient is usually unable to keep his mouth closed. In such cases the device can be adapted with a holder as described below.
  • As illustrated in FIG. 3, the tube [0062] 20 and sensor 22 are part of an instrument 24 that includes a flexible cable 26 that extends to a test instrument 30 that typically indicates the blood flow which provides an indicia of a degree of perfusion failure. While the tube 20 is substantially rigid, the cable 26 is flexible. The cable 26 can be made highly flexible for ease of use, instead of having only the moderate flexibility of a catheter. Usually catheters require enough flexibility to pass through curved body passages, but yet must be resistant to column-type collapse in order to withstand the force applied to the catheter's proximal end necessary to accomplish insertion of the distal end and movement of the distal end along the body passage. Since the cable 26 in the device of FIG. 3 does not have to be pushed, it can have more flexibility for ease of use. The largely rigid tube 20 preferably has a length of no more than about one foot (one-third meter), since a longer length would be cumbersome. Catheters for insertion through the esophagus into the stomach, generally have a length of much more than two feet. FIG. 4 shows an example of a sensor 212, which lies against the sublingual mucosal surface.
  • FIG. 5 shows a preferred embodiment of the device of the invention that is suitable for taking sublingual blood flow measurements. In this embodiment, sensor assembly instrument [0063] 214 may be held in position by a sensor holder 202 that is shaped to lie primarily in a patient's mouth. The holder 202 forms a holder passage 204 that extends between the inner and outer portions 202, 226 of the holder. When located in place, the sensor 214 projects inwardly from the holder and substantially directly contacts the mucosal surface of the patient. The frame may have an outer end that lies outside the patient's mouth.
  • The holder [0064] 202 can serve to prevent discomfort to the patient. To this end, the sublingual inner portion 226, including portions 222 and 224, of the holder preferably lies close to the walls of the mouth on opposite sides of the sensor 214, as well as above and below the sensor. The upper surface 206 of the holder is designed so the tongue T can lie on at least its inner portion, to further provide a seal and to support the tongue to avoid tiring the patient. The holder 202 can also serve as an aid to prevent drying of the oral-nasal cavity.
  • While the holder is an exemplary and preferred isolating means for use with the present invention, other isolating means that serve substantially the same function can be substituted or used in conjunction with the holder. For example, a sheath can surround the blood-flow sensor. The sensor and the sheath can be held in place by a holder similar to that described above, but with the advantage that the entire device may be of an overall smaller size (e.g., for placement in the mouth). [0065]
  • A second purpose of the holder is to substantially fix the position of the sensor assembly [0066] 214 and the sensor 212 so the sensor is maintained in a proper position and does not move. This is particularly useful where the patient is incapable of holding the sensor properly in place due to unconsciousness or some other reason. A tension coil spring extending between the handle and holder, can be used to gently urge the sensor 212 inwardly, where necessary. The holder 202 is preferably formed of an elastomeric material (Young's modulus of less than 50,000 psi) such as a soft rubber or soft foam, to avoid high localized pressure on the patient's mouth that could cause discomfort. In one embodiment, the sensor is positioned on either side of the frenulum of the tongue. The rear portion of the holder 226 may be shaped, as with a slot or bevel, to comfortably receive the frenulum, so the sublingual inner portion can lie close to the inner end of the sublingual area and therefore closely around the blood-flow sensor.
  • In an alternative embodiment, the sensor can be placed adjacent any mucosal surface accessible by the mouth or nose and connecting with any region of the GI tract or upper respiratory/digestive tract.. For example, in FIG. 6 the sensor [0067] 230 can be placed at a gingival mucosal surface W that lies between a lip X and the teeth Y of the patient. The area at the rear of the upper or lower lips X, Z is a mucosal surface. FIGS. 6 and 7 illustrate a holder 230 suitable for use at a mucosal surface adjacent a patient's lips. In this embodiment, holder 230 is preferably of soft elastomeric material such as an elastomeric solid or a foam, or even a viscous fluid in a flexible shell. The holder isolates the mucosal surface area contacted by the sensor and prevents movement of the sensor.
  • In another embodiment, the blood-flow sensor [0068] 240 lies adjacent a mucosal surface area AA in the vestibule of the nasal cavity of a patient (FIG. 8). A foam plug 242 serves as a holder that holds the sensor to position it. Only a pair of electrical wires 244 extend from the sensor through the holder. Where the blood-flow sensor is a fiber optical sensor, the holder can be adapted accordingly so that only the optical fiber extends from the plug.
  • In another embodiment, the blood-flow sensor may be placed adjacent any mucosal surface in the nasal cavity of a patient. [0069]
  • In another embodiment, the blood-flow sensor may be placed adjacent any mucosal surface in the middle nasal conchae of a patient. [0070]
  • In another embodiment, the blood-flow sensor may be placed adjacent any mucosal surface in the inferior nasal conchae of a patient. [0071]
  • In another embodiment, the blood-flow sensor may be placed adjacent any mucosal surface in the choana of a patient. [0072]
  • In another embodiment, the blood-flow sensor may be placed adjacent any mucosal surface in the pharyngeal opening of the auditory tube of a patient. [0073]
  • In another embodiment, the blood-flow sensor may be placed adjacent any mucosal surface in the pharynx of a patient. [0074]
  • In another embodiment, the blood-flow sensor may be placed adjacent any mucosal surface in the oropharyngeal passage of a patient. [0075]
  • In another embodiment, the blood-flow sensor may be placed adjacent a mucosal surface in the stomach of a patient. [0076]
  • In another embodiment, the blood-flow sensor may be placed adjacent a mucosal surface in the jejunum of a patient. [0077]
  • In another embodiment, the blood-flow sensor may be placed adjacent a mucosal surface in the colon of a patient. [0078]
  • In another embodiment, the blood-flow sensor may be placed adjacent a mucosal surface in the rectum of a patient. [0079]
  • In another embodiment, a PCO[0080] 2 sensor may be used in conjunction with the blood-flow sensor. Alternatively, a pH sensor may be used in conjunction with the blood-flow sensor. In a further embodiment, both a pH sensor and a PCO2 sensor may be used in conjunction with the blood-flow sensor. The advantages of such a combination in providing a more robust indication of perfusion failure will be well understood by those skilled in the art.
  • The blood-flow sensor used in the methods and devices of the invention may be any blood-flow sensor suitable for detection of blood flow in the manner described herein, such as laser-Doppler blood-flow sensors, ultrasound-Doppler blood-flow sensors, imaging sensors and so forth. For example, the preferred blood-flow sensor is a laser-Doppler blood-flow sensor. [0081]
  • An exemplary blood-flow sensor of this type is manufactured by Vasomedics (2963 Yorkton Blvd., St. Paul, Minn. 55117-1064; (800) 695-2737)). For example, the Laserflo BPM[0082] 2 may be used to provide continuous tissue perfusion data which can be used to practice the present invention.
  • Thus, the invention provides a method and device for assessing perfusion failure, which methods may be performed rapidly, with little equipment set-up required, and with minimal or substantially no invasion, and thus minimal risk of harm to the patient and an improved probability of patient compliance. The method generally involves introducing a blood-flow sensor adjacent any mucosal surface accessible by the mouth or nose and connecting with the GI tract of a patient, or the upper respiratory/digestive tract of a patient. Furthermore, the method can be performed so as to avoid even triggering the gag reflex of the patient by placing the blood-flow sensor in the upper respiratory/digestive tract at a position generally above the epiglottis. Measurements of blood flow are taken while the sensor is held adjacent a mucosal surface in the upper respiratory/digestive tract, such as a mucosal surface of the mouth or nose, for example the area under the tongue, an area between the upper or lower lip and the teeth, or an area in the nose. A holder may be optionally used to prevent sensor movement The invention is useful in a variety of settings, such as in triage in emergency and disaster settings, monitoring in anesthesia, intensive care, and other acute settings in which patients may have acute perfusion failure (shock). [0083]
  • It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, that the foregoing description as well as the examples which follow are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains. All patents, patent applications, journal articles and other references mentioned herein are incorporated by reference in their entireties. [0084]

Claims (38)

What is claimed is:
1. A device for assessing the degree of systemic perfusion in a patient, the device comprising:
a blood-flow sensor, adapted to be positioned adjacent a mucosal surface within a patient's body and measuring blood flow in adjacent tissue;
a PCO2 sensor, adapted to be positioned adjacent the mucosal surface and measuring PCO2 in the adjacent tissue; and
an indicating means operably connected to the sensor means, for indicating the measured blood flow and the measured PCO2 whereby the degree of systemic perfusion of the patient may be deduced.
2. The device of claim 1, wherein the mucosal surface is in the gastrointestinal tract.
3. The device of claim 2, wherein the mucosal surface is in the esophagus.
4. The device of claim 2, wherein the mucosal surface is in the stomach.
5. The device of claim 2, wherein the mucosal surface is in the jejunum.
6. The device of claim 2, wherein the mucosal surface is in the colon.
7. The device of claim 2, wherein the mucosal surface is in the rectum.
8. The device of claim 1, wherein the mucosal surface is in the upper respiratory/digestive tract.
9. The device of claim 8, wherein the mucosal surface is in the nasal passages.
10. The device of claim 9, wherein the mucosal surface is in the vestibule of the nasal cavity.
11. The device of claim 9, wherein the mucosal surface is in the nasal cavity.
12. The device of claim 9, wherein the mucosal surface is in the middle nasal conchae.
13. The device of claim 9, wherein the mucosal surface is in the inferior nasal conchae.
14. The device of claim 9, wherein the mucosal surface is in the choana.
15. The device of claim 9, wherein mucosal surface is in the pharyngeal opening of the auditory tube.
16. The device of claim 8, wherein the mucosal surface is in the oral cavity.
17. The device of claim 8, wherein the mucosal surface is in the pharynx.
18. The device of claim 8, wherein the mucosal surface is in the oropharyngeal passage.
19. The device of claim 1, wherein the mucosal surface is accessible by a mouth and connects with the gastrointestinal tract.
20. The device of claim 1, wherein the mucosal surface is accessible by a nose and connects with the upper respiratory/digestive tract.
21. The device of claim 15, wherein the mucosal surface is a sublingual surface.
22. The device of claim 1, wherein the device further comprises a positioning means for locating or maintaining the blood flow sensor at a position in the upper respiratory/digestive tract.
23. The device of claim 22, wherein the positioning means is a holder adapted to fit within the oral-nasal cavity of the patient and maintain the blood flow sensor in place adjacent the mucosal surface.
24. The device of claim 23, wherein the positioning means is a holder adapted to fit within the mouth of the patient and hold the blood flow sensor in place adjacent the mucosal surface.
25. The device of claim 23, wherein the holder is adapted to position the blood flow sensor adjacent a sublingual mucosal surface.
26. The device of claim 23, wherein the holder is constructed to fit between the inside of a lip and gum of the patient.
27. The device of claim 23, wherein the positioning means is a holder adapted to fit within the vestibule of the nasal cavity of the patient and hold the sensor in place adjacent the mucosal surface.
28. The device of claim 1, wherein the blood-flow sensor is a laser-Doppler blood-flow sensor.
29. The device of claim 1, wherein the blood-flow sensor is an ultrasound-Doppler blood-flow sensor.
30. The device of claim 1, further comprising a pH sensor.
31. The device of claim 1, further including a means for determining the rate of change of blood flow.
32. The device of claim 31 wherein the determining means comprises a circuit for generating a signal representing rate-of-change of blood flow.
33. A device for assessing the degree of systemic perfusion in a patient, the device comprising:
a blood-flow sensor, adapted to be positioned adjacent a mucosal surface within a patient's body and measuring blood flow in adjacent tissue;
an indicating means operably connected to the sensor means, for indicating the measured blood flow whereby the degree of systemic perfusion of the patient may be deduced; and
a sensor holder with an inner portion and an outer portion, said inner portion shaped to fit in the mouth of a patient under the patient's tongue, said holder forming at least one holder passage extending from said outer portion to said inner portion, wherein the sensor is located within the holder passage.
34. The device of claim 33, wherein the sensor holder has an upper surface that supports the tongue of the patient.
35. The device of claim 33, wherein the outer portion has a slot for receiving the patient's frenulum, and the holder passage has an inner end lying on one side of said slot.
36. The device of claim 33, wherein at least a portion of the holder is comprised of an elastomeric material.
37. A device for assessing the degree of systemic perfusion in a patient, the device comprising:
a blood-flow sensor, adapted to be positioned adjacent a mucosal surface within a patient's body and measuring blood flow in adjacent tissue;
a pH sensor, adapted to be positioned adjacent the mucosal surface and measuring pH in the adjacent tissue; and
an indicating means operably connected to the sensor means, for indicating the measured blood flow and the measured pH whereby the degree of systemic perfusion of the patient may be deduced.
38. A device for assessing the degree of systemic perfusion in a patient, the device comprising:
a blood-flow sensor, adapted to be positioned adjacent a mucosal surface accessible by a mouth and connecting with an upper respiratory/digestive tract in a patient's body and measuring blood flow in adjacent tissue;
an indicating means operably connected to the sensor means, for indicating the measured blood flow whereby the degree of systemic perfusion of the patient may be deduced; and
a sensor holder adapted to hold the blood-flow sensor adjacent the upper respiratory/digestive tract mucosal surface.
US10/357,996 1995-07-06 2003-02-04 Device for assessing perfusion failure in a patient by measurement of blood flow Abandoned US20030220551A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US08/498,932 US5579763A (en) 1995-07-06 1995-07-06 Measurement of systemic perfusion
US71020896A true 1996-09-13 1996-09-13
US93959197A true 1997-09-29 1997-09-29
US09/099,293 US6055447A (en) 1995-07-06 1998-06-18 Patient CO2 Measurement
US09/160,224 US6216024B1 (en) 1995-07-06 1998-09-24 Method and device for assessing perfusion failure in a patient
US09/285,409 US6258046B1 (en) 1995-07-06 1999-04-02 Method and device for assessing perfusion failure in a patient by measurement of blood flow
US09/866,042 US20010025151A1 (en) 1995-07-06 2001-05-24 Device for assessing perfusion failure in a patient by measurement of blood flow
US10/357,996 US20030220551A1 (en) 1995-07-06 2003-02-04 Device for assessing perfusion failure in a patient by measurement of blood flow

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/357,996 US20030220551A1 (en) 1995-07-06 2003-02-04 Device for assessing perfusion failure in a patient by measurement of blood flow
US10/668,750 US20040127800A1 (en) 1995-07-06 2003-09-23 Device for assessing perfusion failure in a patient by measurement of blood flow

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/866,042 Continuation-In-Part US20010025151A1 (en) 1995-07-06 2001-05-24 Device for assessing perfusion failure in a patient by measurement of blood flow

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/668,750 Continuation-In-Part US20040127800A1 (en) 1995-07-06 2003-09-23 Device for assessing perfusion failure in a patient by measurement of blood flow

Publications (1)

Publication Number Publication Date
US20030220551A1 true US20030220551A1 (en) 2003-11-27

Family

ID=23094111

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/285,409 Expired - Lifetime US6258046B1 (en) 1995-07-06 1999-04-02 Method and device for assessing perfusion failure in a patient by measurement of blood flow
US09/866,042 Abandoned US20010025151A1 (en) 1995-07-06 2001-05-24 Device for assessing perfusion failure in a patient by measurement of blood flow
US10/357,996 Abandoned US20030220551A1 (en) 1995-07-06 2003-02-04 Device for assessing perfusion failure in a patient by measurement of blood flow

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/285,409 Expired - Lifetime US6258046B1 (en) 1995-07-06 1999-04-02 Method and device for assessing perfusion failure in a patient by measurement of blood flow
US09/866,042 Abandoned US20010025151A1 (en) 1995-07-06 2001-05-24 Device for assessing perfusion failure in a patient by measurement of blood flow

Country Status (6)

Country Link
US (3) US6258046B1 (en)
EP (1) EP1164924A4 (en)
JP (1) JP2002540831A (en)
AU (1) AU768377B2 (en)
CA (1) CA2369055A1 (en)
WO (1) WO2000059372A1 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070208252A1 (en) * 2004-04-21 2007-09-06 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US20080132938A1 (en) * 2004-04-21 2008-06-05 Acclarent, Inc. Devices, Systems and Methods for Treating Disorders of the Ear, Nose and Throat
US20100280398A1 (en) * 2007-12-21 2010-11-04 Institute Of National Colleges Of Technology, Japan Laser doppler blood flow measuring method and device
US20110213264A1 (en) * 2010-02-26 2011-09-01 Nellcor Puritan Bennett Llc Sensor on non-sealing portion of tracheal tube cuff
US20110213214A1 (en) * 2010-02-26 2011-09-01 Nellcor Puritan Bennett Llc Mechanically deployable tracheal tube sensor
US20110230742A1 (en) * 2010-03-17 2011-09-22 Nellcor Puritan Bennett Llc Tracheal tube sensor disposed on permeable membrane
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US8715169B2 (en) 2004-04-21 2014-05-06 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8721591B2 (en) 2004-04-21 2014-05-13 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US8870893B2 (en) 2004-04-21 2014-10-28 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US8961398B2 (en) 2004-04-21 2015-02-24 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
US9089258B2 (en) 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US9107574B2 (en) 2004-04-21 2015-08-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
US9265407B2 (en) 2004-04-21 2016-02-23 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9308361B2 (en) 2005-01-18 2016-04-12 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US9468362B2 (en) 2004-04-21 2016-10-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US9826999B2 (en) 2004-04-21 2017-11-28 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127800A1 (en) * 1995-07-06 2004-07-01 Kimball Victor E. Device for assessing perfusion failure in a patient by measurement of blood flow
US8133177B2 (en) * 2003-09-23 2012-03-13 Vasamed, Inc. System and method for assessing capillary vitality
US6773405B2 (en) * 2000-09-15 2004-08-10 Jacob Fraden Ear temperature monitor and method of temperature measurement
US20020087057A1 (en) * 2000-12-29 2002-07-04 Lovejoy David Anthony Method and apparatus for assessing tissue perfusion
EP1401321A4 (en) * 2001-05-17 2005-08-24 Thermal Technologies Inc Blood flow monitor for shock and resuscitation
US20040068201A1 (en) * 2002-02-15 2004-04-08 Eunoe, Inc. Systems and methods for flow detection and measurement in CSF shunts
US20060161055A1 (en) * 2002-03-20 2006-07-20 Critisense, Ltd. Probe design
IL148795D0 (en) * 2002-03-20 2002-09-12 Vital Medical Ltd Apparatus and method for monitoring tissue vitality parameters for the diagnosis of body metabolic emergency state
US7569021B2 (en) 2002-03-21 2009-08-04 Jolife Ab Rigid support structure on two legs for CPR
US8996090B2 (en) * 2002-06-03 2015-03-31 Exostat Medical, Inc. Noninvasive detection of a physiologic parameter within a body tissue of a patient
US6684680B2 (en) 2002-06-03 2004-02-03 Optical Sensors, Inc. Cartridge for packaging a sensor in a fluid calibrant
US7308304B2 (en) 2003-02-14 2007-12-11 Medtronic Physio-Control Corp. Cooperating defibrillators and external chest compression devices
US20040162510A1 (en) * 2003-02-14 2004-08-19 Medtronic Physio-Control Corp Integrated external chest compression and defibrillation devices and methods of operation
US20050038475A1 (en) * 2003-02-18 2005-02-17 Medtronic Physio-Control Corp. Defibrillators learning of other concurrent therapy
US7569018B1 (en) 2003-02-18 2009-08-04 Purdue Research Foundation Apparatus and method for noninvasively detecting the quality of cardiac pumping
US7785266B2 (en) * 2003-08-19 2010-08-31 Advanced Monitors Corporation Medical thermometer for determining body core temperature
US7938783B2 (en) * 2003-08-19 2011-05-10 Advanced Monitors Corporation Medical body core thermometer
US9254220B1 (en) 2006-08-29 2016-02-09 Vasamed, Inc. Method and system for assessing severity and stage of peripheral arterial disease and lower extremity wounds using angiosome mapping
US7485094B2 (en) * 2003-09-30 2009-02-03 Smithmarks, Inc. Methods of diagnosis using pulse volume measurement
US7122047B2 (en) * 2003-11-14 2006-10-17 The Board Of Trustees Of The Leland Stanford Junior University Controlled heat transfer with mammalian bodies
US8369920B2 (en) * 2004-03-09 2013-02-05 Institute Of Critical Care Medicine Mucosal sensor adaptor
US20060058690A1 (en) 2004-09-10 2006-03-16 Optical Sensors, Inc. Method and instrument for automated measurement of skin perfusion pressure
NL1028320C2 (en) * 2005-02-17 2006-08-21 Drs Jan Beute Measuring member and device for determining the blood flow of the gastrointestinal tract, as well as the recording of the intestinal peristalsis.
US20060266366A1 (en) * 2005-05-25 2006-11-30 Ross Tsukashima Illumination means for catheter placement
RU2309668C1 (en) 2006-02-20 2007-11-10 Александр Сергеевич Парфенов Method and device for non-invasive measurement of function of endothelium
US7643879B2 (en) 2006-08-24 2010-01-05 Cardiac Pacemakers, Inc. Integrated cardiac rhythm management system with heart valve
US9717896B2 (en) 2007-12-18 2017-08-01 Gearbox, Llc Treatment indications informed by a priori implant information
US20090287120A1 (en) 2007-12-18 2009-11-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Circulatory monitoring systems and methods
US8636670B2 (en) 2008-05-13 2014-01-28 The Invention Science Fund I, Llc Circulatory monitoring systems and methods
JPWO2010053085A1 (en) * 2008-11-04 2012-04-05 出光興産株式会社 Acidosis control agent of the ruminant
US8057400B2 (en) 2009-05-12 2011-11-15 Angiologix, Inc. System and method of measuring changes in arterial volume of a limb segment
CN103750802A (en) * 2011-12-30 2014-04-30 广州宝胆医疗器械科技有限公司 Capsule enteroscope system with Doppler laser function
CN103750803A (en) * 2011-12-30 2014-04-30 广州宝胆医疗器械科技有限公司 Capsule enteroscope system with two-way Doppler laser function
WO2013149264A1 (en) * 2012-03-30 2013-10-03 The Regents Of The University Of California System, device and method for measurement of esophageal wall blood perfusion
JP2014057580A (en) * 2012-09-14 2014-04-03 Kenji Ryotokuji Methods to promote expression of genes which activate homeostatic functions
US9700215B2 (en) 2012-10-24 2017-07-11 Makaha Medical, Llc. Systems and methods for assessing vasculature health and blood clots
FR3016509B1 (en) * 2014-01-17 2018-03-30 Apd Advanced Perfusion Diagnostics Device for measuring blood data to estimate the quality of microcirculatory flow
US10004662B2 (en) 2014-06-06 2018-06-26 Physio-Control, Inc. Adjustable piston
US10092464B2 (en) 2014-10-03 2018-10-09 Physio-Control, Inc. Medical device stabilization strap
WO2018112458A1 (en) * 2016-12-16 2018-06-21 Infusense Corp. Compositions and methods to detect molecules in a sample

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511227A (en) 1967-02-27 1970-05-12 Univ Utah Measurement of blood flow using coherent radiation and doppler effect
US3905889A (en) 1974-11-01 1975-09-16 Gen Electric Miniature multifunctional electrochemical sensor for simultaneous carbon dioxide-pH measurements
US4109647A (en) 1977-03-16 1978-08-29 The United States Of America As Represented By The Secretary Of The Department Of Health, Education And Welfare Method of and apparatus for measurement of blood flow using coherent light
US4324258A (en) 1980-06-24 1982-04-13 Werner Huebscher Ultrasonic doppler flowmeters
US4643192A (en) 1982-03-22 1987-02-17 Regents Of The University Of Michigan Hollow viscus tonometry
IL68115A (en) * 1983-03-14 1987-03-31 Rosenberg Lior Fluid flow detector particularly useful for microvascular monitoring
SE8400289D0 (en) 1984-01-20 1984-01-20 Perimed Kb Seen and apparatus for bestemning of blood flow in the superficial blodkerlen of a vevnad
US4596254A (en) 1984-12-18 1986-06-24 Tsi Research Associates Limited Partnership Laser Doppler flow monitor
US4722347A (en) * 1985-01-15 1988-02-02 Applied Biometrics, Inc. Apparatus for measuring cardiac output
US4759374A (en) 1985-05-06 1988-07-26 American Telephone And Telegraph Company And At&T Bell Laboratories Non-invasive blood flow measurements utilizing cardiac cycle synchronization
FR2584288A1 (en) * 1985-07-08 1987-01-09 Bazenet Jean Pierre probe type intracorporeal probe esophageal and mounting device balloons of such a probe
US4632119A (en) 1985-10-23 1986-12-30 University Of Health Sciences/The Chicago Medical School Ambulatory esophageal pH monitor
US4919891A (en) 1986-04-18 1990-04-24 Minnesota Mining And Manufacturing Company Sensor with overcoating and process for making same
US4800886A (en) 1986-07-14 1989-01-31 C. R. Bard, Inc. Sensor for measuring the concentration of a gaseous component in a fluid by absorption
US4785814A (en) 1987-08-11 1988-11-22 Cordis Corporation Optical probe for measuring pH and oxygen in blood and employing a composite membrane
US4842783A (en) 1987-09-03 1989-06-27 Cordis Corporation Method of producing fiber optic chemical sensors incorporating photocrosslinked polymer gels
JPS6462128A (en) * 1987-09-03 1989-03-08 Olympus Optical Co Ultrasonic pulse doppler blood flowmeter
US4945896A (en) * 1989-01-24 1990-08-07 Gade George F Surgical retractor assembly having tissue viability sensor embedded therein
US4892383A (en) 1989-02-17 1990-01-09 Fiberchem Inc. Reservoir fiber optic chemical sensors
US4981470A (en) 1989-06-21 1991-01-01 Synectics Medical, Inc. Intraesophageal catheter with pH sensor
US5098659A (en) 1990-09-24 1992-03-24 Abbott Laboratories Apparatus for continuously monitoring a plurality of chemical analytes through a single optical fiber and method of making
JP3072910B2 (en) * 1990-11-01 2000-08-07 孝一 桜井 Biological surface blood flow measuring device
US5280548A (en) 1993-03-11 1994-01-18 Boc Health Care, Inc. Emission based fiber optic sensors for pH and carbon dioxide analysis
US5607644A (en) 1993-06-10 1997-03-04 Optical Sensors Incorporated Optical sensor for the measurement of pH in a fluid, and related sensing compositions and methods
US5620000A (en) 1993-07-02 1997-04-15 Heidelberg Engineering, Optische Messsysteme Gmbh Method and apparatus for measuring flow rate, particularly of blood
GB9411231D0 (en) 1994-06-04 1994-07-27 Kellam Keith Laser doppler microscopy methods and instruments
JPH0947432A (en) * 1995-05-31 1997-02-18 Life Tec Kenkyusho:Kk Oral cavity tissue observation device
US5579763A (en) 1995-07-06 1996-12-03 Institute Of Critical Care Medicine Measurement of systemic perfusion
US5672515A (en) 1995-09-12 1997-09-30 Optical Sensors Incorporated Simultaneous dual excitation/single emission fluorescent sensing method for PH and pCO2
US5714121A (en) 1995-09-28 1998-02-03 Optical Sensors Incorporated Optical carbon dioxide sensor, and associated methods of manufacture
US5766127A (en) * 1996-04-15 1998-06-16 Ohmeda Inc. Method and apparatus for improved photoplethysmographic perfusion-index monitoring
IL120881A (en) * 1996-07-30 2002-09-12 It M R Medic L Cm 1997 Ltd Method and apparatus for the non-invasive continous monitoring of peripheral arterial tone
GB9623363D0 (en) 1996-11-09 1997-01-08 Moor Instr Ltd Apparatus for measuring microvascular blood flow

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US20080132938A1 (en) * 2004-04-21 2008-06-05 Acclarent, Inc. Devices, Systems and Methods for Treating Disorders of the Ear, Nose and Throat
US10098652B2 (en) 2004-04-21 2018-10-16 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US10034682B2 (en) 2004-04-21 2018-07-31 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US9826999B2 (en) 2004-04-21 2017-11-28 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US9814379B2 (en) 2004-04-21 2017-11-14 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US20070208252A1 (en) * 2004-04-21 2007-09-06 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US8715169B2 (en) 2004-04-21 2014-05-06 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8721591B2 (en) 2004-04-21 2014-05-13 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US9649477B2 (en) 2004-04-21 2017-05-16 Acclarent, Inc. Frontal sinus spacer
US8764726B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8777926B2 (en) 2004-04-21 2014-07-15 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasel or paranasal structures
US8828041B2 (en) 2004-04-21 2014-09-09 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8852143B2 (en) 2004-04-21 2014-10-07 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8858586B2 (en) 2004-04-21 2014-10-14 Acclarent, Inc. Methods for enlarging ostia of paranasal sinuses
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US8870893B2 (en) 2004-04-21 2014-10-28 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8905922B2 (en) 2004-04-21 2014-12-09 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US9610428B2 (en) 2004-04-21 2017-04-04 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8961495B2 (en) 2004-04-21 2015-02-24 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8961398B2 (en) 2004-04-21 2015-02-24 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
US9554691B2 (en) 2004-04-21 2017-01-31 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9167961B2 (en) 2004-04-21 2015-10-27 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US9055965B2 (en) 2004-04-21 2015-06-16 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9089258B2 (en) 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US9107574B2 (en) 2004-04-21 2015-08-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9468362B2 (en) 2004-04-21 2016-10-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US9370649B2 (en) 2004-04-21 2016-06-21 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9220879B2 (en) 2004-04-21 2015-12-29 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9241834B2 (en) 2004-04-21 2016-01-26 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US9265407B2 (en) 2004-04-21 2016-02-23 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8764709B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US9308361B2 (en) 2005-01-18 2016-04-12 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US10124154B2 (en) 2005-06-10 2018-11-13 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US9179823B2 (en) 2006-09-15 2015-11-10 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US9572480B2 (en) 2006-09-15 2017-02-21 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9603506B2 (en) 2006-09-15 2017-03-28 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US20100280398A1 (en) * 2007-12-21 2010-11-04 Institute Of National Colleges Of Technology, Japan Laser doppler blood flow measuring method and device
US9031640B2 (en) * 2007-12-21 2015-05-12 Institute Of National Colleges Of Technology, Japan Laser doppler blood flow measuring method and device
US20110213264A1 (en) * 2010-02-26 2011-09-01 Nellcor Puritan Bennett Llc Sensor on non-sealing portion of tracheal tube cuff
US20110213214A1 (en) * 2010-02-26 2011-09-01 Nellcor Puritan Bennett Llc Mechanically deployable tracheal tube sensor
US9044557B2 (en) 2010-03-17 2015-06-02 Covidien Lp Tracheal tube sensor disposed on permeable membrane
US20110230742A1 (en) * 2010-03-17 2011-09-22 Nellcor Puritan Bennett Llc Tracheal tube sensor disposed on permeable membrane
US8568316B2 (en) 2010-03-17 2013-10-29 Covidien Lp Tracheal tube sensor disposed on permeable membrane
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device

Also Published As

Publication number Publication date
WO2000059372A1 (en) 2000-10-12
US20010025151A1 (en) 2001-09-27
CA2369055A1 (en) 2000-10-12
JP2002540831A (en) 2002-12-03
EP1164924A4 (en) 2003-04-02
EP1164924A1 (en) 2002-01-02
AU4061400A (en) 2000-10-23
US6258046B1 (en) 2001-07-10
AU768377B2 (en) 2003-12-11
WO2000059372A9 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
Kramer et al. Oesophageal sensitivity to Mecholyl in symptomatic diffuse spasm.
EP1267711B1 (en) Apparatus for measuring the compliance of a sphincter
JP3625475B2 (en) Noninvasively system for monitoring the hematocrit
US5622182A (en) System for measuring core body temperature in vivo
Lima et al. Noninvasive monitoring of peripheral perfusion
US9380951B2 (en) Non-invasively monitoring blood parameters
US7322971B2 (en) Surgical drain with sensors for monitoring internal tissue condition by transmittance
US6292689B1 (en) Apparatus and methods of bioelectrical impedance analysis of blood flow
EP1558133B1 (en) Apparatus for monitoring blood condition and cardiopulmonary function
US5817009A (en) Arrangement for noninvasive determination of the oxygen saturation in human blood vessels or organs
US6865407B2 (en) Calibration technique for non-invasive medical devices
RU2248813C2 (en) Mask having sensing elements for performing current patient control
US5788631A (en) Hollow viscus and solid organ tonometry
CA2051419C (en) Device for use in real-time monitoring of human or animal bodily functions
US5551424A (en) Fetal probe apparatus
US5957839A (en) Apparatus and method for continuous monitoring of tissue gas composition and pH using recirculating gas tonometry
Swoger et al. Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study
US20040215093A1 (en) Measurement of cardiac output and blood volume by non-invasive detection of indicator dilution
JP4751338B2 (en) Nasal pulse oximeter of new and special configuration
US4773430A (en) Method and apparatus for the localization of bleeding in the gastrointestinal tract
JP2795882B2 (en) Enteral feeding device utilizing gastrointestinal electromyogram
US20130324866A1 (en) Indications of cross-section of small branched blood vessels
US20050222502A1 (en) Methods and apparatus for patient monitoring
US9420967B2 (en) Apparatus, systems and methods for determining tissue oxygenation
Escorsell et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension

Legal Events

Date Code Title Description
AS Assignment

Owner name: OPTICAL SENSORS INCORPORATED, MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KIMBALL, VICTOR E.;REEL/FRAME:014106/0023

Effective date: 20030226

AS Assignment

Owner name: INSTITUTE OF CRITICAL CARE MEDICINE, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEIL, MAX HARRY;TANG, WANCHUN;BISERA, JOSE;REEL/FRAME:014106/0020

Effective date: 20030514

AS Assignment

Owner name: WEIL INSTITUTE OF CRITICAL CARE MEDICINE, CALIFORN

Free format text: CHANGE OF NAME;ASSIGNOR:INSTITUTE OF CRITICAL CARE MEDICINE;REEL/FRAME:033180/0021

Effective date: 20110513